Aisha Sati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aisha Sati has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hanne Dhondt
Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
9 shared publications - Nina Schoonvliet
Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
5 shared publications Ana Catarina Carapinha Cascalho
4 shared publications- Elena Coccia
Icahn School of Medicine Icahn School of Medicine Mount Sinai Mount Sinai
2 shared publications - Joel Blanchard
Nash Family Department of Neuroscience & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
2 shared publications - Peter Vangheluwe
Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
2 shared publications
Latest Publications
- Open Access
Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency
Pathogenic variants in ATP13A2 , which encodes an endolysosomal polyamine exporter, cause Kufor-Rakeb syndrome and are associated with early-onset parkinsonism and related neurodegenerative disorders; however, the mechanisms by which ATP13A2 dysfunction drives disease remain incompletely defined. In Atp13a2 knockout mice, we identified an early, transient reduction in brain polyamines that precedes overt gliosis and behavioural abnormalities. Pharmacological polyamine depletion exacerbates phenotypes, whereas oral supplementation of spermidine, but not spermine, rescues parkinsonian symptoms establishing metabolic polyamine deficiency as a pathogenic driver. Mechanistically, spermidine counteracts microglia lysosomal dysfunction in the brain and exerts mitochondrial antioxidant and anti-inflammatory effects in primary mouse microglia, thereby improving neuronal integrity. In the absence of Atp13a2, microglial spermidine import relies on the related polyamine transporter Atp13a3. Importantly, these findings translate to human systems, whereby spermidine attenuates inflammation in ATP13A2-deficient human differentiated microglia, while postmortem ATP13A2-deficient brain analysis confirms increased microglia reactivity. Spermidine also rescues motor deficits and dopaminergic neuron loss in ATP13A2-deficient Drosophila and other fly parkinsonism models. Together, these findings identify early polyamine dysregulation as a mechanistic contributor to ATP13A2-associated parkinsonism and nominate spermidine supplementation as a potential therapeutic strategy for ATP13A2-driven pathology and possibly a broader range of parkinsonian sub-types.
Open AccessSpermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency
Pathogenic variants in ATP13A2 , which encodes an endolysosomal polyamine exporter, cause Kufor-Rakeb syndrome and are associated with early-onset parkinsonism and related neurodegenerative disorders; however, the mechanisms by which ATP13A2 dysfunction drives disease remain incompletely defined. In Atp13a2 knockout mice, we identified an early, transient reduction in brain polyamines that precedes overt gliosis and behavioural abnormalities. Pharmacological polyamine depletion exacerbates phenotypes, whereas oral supplementation of spermidine, but not spermine, rescues parkinsonian symptoms establishing metabolic polyamine deficiency as a pathogenic driver. Mechanistically, spermidine counteracts microglia lysosomal dysfunction in the brain and exerts mitochondrial antioxidant and anti-inflammatory effects in primary mouse microglia, thereby improving neuronal integrity. In the absence of Atp13a2, microglial spermidine import relies on the related polyamine transporter Atp13a3. Importantly, these findings translate to human systems, whereby spermidine attenuates inflammation in ATP13A2-deficient human differentiated microglia, while postmortem ATP13A2-deficient brain analysis confirms increased microglia reactivity. Spermidine also rescues motor deficits and dopaminergic neuron loss in ATP13A2-deficient Drosophila and other fly parkinsonism models. Together, these findings identify early polyamine dysregulation as a mechanistic contributor to ATP13A2-associated parkinsonism and nominate spermidine supplementation as a potential therapeutic strategy for ATP13A2-driven pathology and possibly a broader range of parkinsonian sub-types.
- Open Access
- 11 April 2026
- Published by Springer Nature
Collection of mouse cerebrospinal fluid from the cisterna magna v1
This protocol describes the collection of mouse cerebrospinal fluid from the cisterna magna.
- 11 April 2026
- Published by Springer Nature
Open AccessCollection of mouse cerebrospinal fluid from the cisterna magna v1
This protocol describes the collection of mouse cerebrospinal fluid from the cisterna magna.
- Open Access
ATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity
Aging is the strongest risk factor for neurodegeneration, yet how the human brain ages remains poorly understood. Loss-of-function (LOF) variants in ATP13A2 cause severe juvenile-onset Parkinson’s disease, providing a window into the mechanisms that accelerate age-related neurodegeneration. ATP13A2-LOF causes lysosomal polyamine sequestration, but how this promotes pathogenesis remains unclear. We discovered that ATP13A2-LOF depletes cytosolic polyamines in astrocytes, triggering compensatory upregulation of de novo polyamine biosynthesis, which diverts S-adenosyl methionine (SAM) from DNA and histone methylation, leading to increased chromatin accessibility and epigenetic reprogramming of astrocytes into a neuroinflammatory state that releases neurotoxic cytokines that promote dopaminergic neuron death. In ATP13A2 knockout mice and human models, we find that genetic and pharmacological inhibition of SAM utilization in polyamine biosynthesis prevents astrocytic epigenetic reprogramming and promotes dopaminergic neuron survival. These findings reveal a direct link between polyamine metabolism, epigenetic dysfunction, and neurotoxic inflammation, uncovering new therapeutic opportunities in Parkinson’s disease.
Open AccessATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity
Aging is the strongest risk factor for neurodegeneration, yet how the human brain ages remains poorly understood. Loss-of-function (LOF) variants in ATP13A2 cause severe juvenile-onset Parkinson’s disease, providing a window into the mechanisms that accelerate age-related neurodegeneration. ATP13A2-LOF causes lysosomal polyamine sequestration, but how this promotes pathogenesis remains unclear. We discovered that ATP13A2-LOF depletes cytosolic polyamines in astrocytes, triggering compensatory upregulation of de novo polyamine biosynthesis, which diverts S-adenosyl methionine (SAM) from DNA and histone methylation, leading to increased chromatin accessibility and epigenetic reprogramming of astrocytes into a neuroinflammatory state that releases neurotoxic cytokines that promote dopaminergic neuron death. In ATP13A2 knockout mice and human models, we find that genetic and pharmacological inhibition of SAM utilization in polyamine biosynthesis prevents astrocytic epigenetic reprogramming and promotes dopaminergic neuron survival. These findings reveal a direct link between polyamine metabolism, epigenetic dysfunction, and neurotoxic inflammation, uncovering new therapeutic opportunities in Parkinson’s disease.
- Open Access
- 17 March 2026
- Published by Springer Nature
Cascalho Sati et al_Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency v1
A collection of protocols used for the generation of all data incorporated into the manuscript titled "Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency"
- 17 March 2026
- Published by Springer Nature
Open AccessCascalho Sati et al_Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency v1
A collection of protocols used for the generation of all data incorporated into the manuscript titled "Spermidine suppresses glial inflammation and parkinsonian abnormalities in ATP13A2 deficiency"
- Open Access
- 27 February 2026
- Published by Springer Nature
Mitoguazone in vivo injections v1
This protocol details a treatment paradigm using mitoguazone in vivo
- 27 February 2026
- Published by Springer Nature
Open AccessMitoguazone in vivo injections v1
This protocol details a treatment paradigm using mitoguazone in vivo
- Open Access
- 24 February 2026
- Published by Springer Nature
Metabolomics for measuring polyamine levels in the plasma, brain and liver of mice v1
This protocol details the analysis of polyamine species in plasma, brain, and liver samples using metabolomics-based approaches.
- 24 February 2026
- Published by Springer Nature
Open AccessMetabolomics for measuring polyamine levels in the plasma, brain and liver of mice v1
This protocol details the analysis of polyamine species in plasma, brain, and liver samples using metabolomics-based approaches.
- Open Access
- 24 February 2026
- Published by Springer Nature
Primary murine microglia, neurons and co-cultures v1
This protocol details the methodology to establish primary murine microglia, neuronal cultures and co-cultures. The protocol also describes methodology for polyamine supplementation in vitro and transfections of siRNA in primary microglia.
- 24 February 2026
- Published by Springer Nature
Open AccessPrimary murine microglia, neurons and co-cultures v1
This protocol details the methodology to establish primary murine microglia, neuronal cultures and co-cultures. The protocol also describes methodology for polyamine supplementation in vitro and transfections of siRNA in primary microglia.
- Open Access
- 24 February 2026
- Published by Springer Nature
MSD Proinflammatory cytokine Panel 1 (mouse) Kit v1
This protocol summarizes the kit instructions to use the V-PLEX Proinflammatory Panel 1 (mouse) Kit.
- 24 February 2026
- Published by Springer Nature
Open AccessMSD Proinflammatory cytokine Panel 1 (mouse) Kit v1
This protocol summarizes the kit instructions to use the V-PLEX Proinflammatory Panel 1 (mouse) Kit.
- Open Access
- 24 February 2026
- Published by Springer Nature
Microglia isolation using magnetic cell sorting from adult mouse brains v1
This protocol details the isolation of microglia using magnetic beads from adult mouse brains.
- 24 February 2026
- Published by Springer Nature
Open AccessMicroglia isolation using magnetic cell sorting from adult mouse brains v1
This protocol details the isolation of microglia using magnetic beads from adult mouse brains.
- Open Access
- 24 February 2026
- Published by Springer Nature
Collection of mouse cerebrospinal fluid from the cisterna magna v1
This protocol describes the collection of mouse cerebrospinal fluid from the cisterna magna.
- 24 February 2026
- Published by Springer Nature
Open AccessCollection of mouse cerebrospinal fluid from the cisterna magna v1
This protocol describes the collection of mouse cerebrospinal fluid from the cisterna magna.